Mizuho Securities analyst Uy Ear maintained a Hold rating on Revance Therapeutics (RVNC – Research Report) yesterday and set a price target of ...

Needham thinks the deal makes strategic sense given Sarepta’s ex Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing ...

SAREPTA, La. -- Working smoke detectors get the credit for a woman surviving a fire in her home Monday night. A woman who ...

New data on Sarepta's gene therapy for Duchenne muscular dystrophy (DMD) has gone a long way towards building confidence in its efficacy – but have introduced a concern about its safety. Updated ...